Skip To Main Content
Partha Sarathi on Muck Rack

Partha Sarathi

As seen in: Medium, arXiv, Frontiers, ACS Publications, Biomed Central (BMC), Product Hunt, DEV Community, Dialnet - Universidad de La Rioja, Texas Medical Center, Journal of Family Medicine and Primary Care and

Get in touch with Partha

Contact Partha, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Computer Science > Information Retrieval

|
By Partha Sarathi
| arXiv
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Open in Who Shared View Duplicates (555) Issue with article?

Black Hole Search: Dynamics, Distribution, and Emergence

|
By Partha Sarathi
| arXiv
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Open in Who Shared View Duplicates (642) Issue with article?

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

|
By Manas Ranjan, Partha Sarathi
| Frontiers
Abstract Current anti-angiogenic therapies using vascular endothelial growth factor-A/vascular endothelial growth factor receptor-2 (VEGF-A/VEGFR2) inhibitors lack dynamic biomarkers that can facilitate patient selection and optimize dosing; this can lead to suboptimal and unsatisfactory outcomes and significant toxicities. To address this, we propose a paradigm shift leveraging the dopamine D2 receptor (DRD2)/VEGF-A paracrine feedback loop.
Open in Who Shared Issue with article?
See all 35 licensed articles (38 Total)